Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells
Advanced Science ( IF 14.3 ) Pub Date : 2021-07-14 , DOI: 10.1002/advs.202003708 Xi Wang 1 , Natalie K Brown 1 , Bo Wang 1 , Kaavian Shariati 1 , Kai Wang 2, 3 , Stephanie Fuchs 1 , Juan M Melero-Martin 2, 3, 4 , Minglin Ma 1
Advanced Science ( IF 14.3 ) Pub Date : 2021-07-14 , DOI: 10.1002/advs.202003708 Xi Wang 1 , Natalie K Brown 1 , Bo Wang 1 , Kaavian Shariati 1 , Kai Wang 2, 3 , Stephanie Fuchs 1 , Juan M Melero-Martin 2, 3, 4 , Minglin Ma 1
Affiliation
|
Islet transplantation has shown promise as a curative therapy for type 1 diabetes (T1D). However, the side effects of systemic immunosuppression and limited long-term viability of engrafted islets, together with the scarcity of donor organs, highlight an urgent need for the development of new, improved, and safer cell-replacement strategies. Induction of local immunotolerance to prevent allo-rejection against islets and stem cell derived β cells has the potential to improve graft function and broaden the applicability of cellular therapy while minimizing adverse effects of systemic immunosuppression. In this mini review, recent developments in non-encapsulation, local immunomodulatory approaches for T1D cell replacement therapies, including islet/β cell modification, immunomodulatory biomaterial platforms, and co-transplantation of immunomodulatory cells are discussed. Key advantages and remaining challenges in translating such technologies to clinical settings are identified. Although many of the studies discussed are preliminary, the growing interest in the field has led to the exploration of new combinatorial strategies involving cellular engineering, immunotherapy, and novel biomaterials. Such interdisciplinary research will undoubtedly accelerate the development of therapies that can benefit the whole T1D population.
中文翻译：
局部免疫调节策略防止胰岛素生产细胞移植中的同种异体排斥
胰岛移植已显示出作为 1 型糖尿病 (T1D) 治疗方法的前景。然而，全身免疫抑制的副作用和移植胰岛的长期生存能力有限，再加上供体器官的稀缺，突出表明迫切需要开发新的、改进的和更安全的细胞替代策略。诱导局部免疫耐受以防止对胰岛和干细胞衍生的β细胞的同种异体排斥，有可能改善移植物功能并扩大细胞治疗的适用性，同时最大限度地减少全身免疫抑制的不利影响。在这篇小综述中，讨论了 T1D 细胞替代疗法的非封装、局部免疫调节方法的最新进展，包括胰岛/ β细胞修饰、免疫调节生物材料平台和免疫调节细胞的共移植。确定了将此类技术转化为临床环境的主要优势和仍然存在的挑战。尽管讨论的许多研究都是初步的，但对该领域日益增长的兴趣导致了对涉及细胞工程、免疫疗法和新型生物材料的新组合策略的探索。这种跨学科研究无疑将加速开发能够造福整个 T1D 人群的疗法。
更新日期：2021-09-09
中文翻译：
局部免疫调节策略防止胰岛素生产细胞移植中的同种异体排斥
胰岛移植已显示出作为 1 型糖尿病 (T1D) 治疗方法的前景。然而，全身免疫抑制的副作用和移植胰岛的长期生存能力有限，再加上供体器官的稀缺，突出表明迫切需要开发新的、改进的和更安全的细胞替代策略。诱导局部免疫耐受以防止对胰岛和干细胞衍生的β细胞的同种异体排斥，有可能改善移植物功能并扩大细胞治疗的适用性，同时最大限度地减少全身免疫抑制的不利影响。在这篇小综述中，讨论了 T1D 细胞替代疗法的非封装、局部免疫调节方法的最新进展，包括胰岛/ β细胞修饰、免疫调节生物材料平台和免疫调节细胞的共移植。确定了将此类技术转化为临床环境的主要优势和仍然存在的挑战。尽管讨论的许多研究都是初步的，但对该领域日益增长的兴趣导致了对涉及细胞工程、免疫疗法和新型生物材料的新组合策略的探索。这种跨学科研究无疑将加速开发能够造福整个 T1D 人群的疗法。
京公网安备 11010802027423号